These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 12131209

  • 1. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.
    AIDS; 2002 Jul 05; 16(10):1331-40. PubMed ID: 12131209
    [Abstract] [Full Text] [Related]

  • 2. Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.
    Tsuchiya K, Matsuoka-Aizawa S, Yasuoka A, Kikuchi Y, Tachikawa N, Genka I, Teruya K, Kimura S, Oka S.
    J Clin Virol; 2003 Aug 05; 27(3):252-62. PubMed ID: 12878089
    [Abstract] [Full Text] [Related]

  • 3. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
    Røge BT, Katzenstein TL, Nielsen HL, Gerstoft J.
    HIV Med; 2003 Jan 05; 4(1):38-47. PubMed ID: 12534958
    [Abstract] [Full Text] [Related]

  • 4. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
    Dronda F, Casado JL, Moreno S, Hertogs K, García-Arata I, Antela A, Pérez-Elías MJ, Ruiz L, Larder B, NELSANE Study.
    AIDS Res Hum Retroviruses; 2001 Feb 10; 17(3):211-5. PubMed ID: 11177403
    [Abstract] [Full Text] [Related]

  • 5. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S.
    AIDS; 1999 Feb 04; 13(2):F17-21. PubMed ID: 10202819
    [Abstract] [Full Text] [Related]

  • 6. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
    Fitzgibbon JE, Gaur S, Walsman SM, Janahi M, Whitley-Williams P, John JF.
    AIDS Res Hum Retroviruses; 2001 Sep 20; 17(14):1321-8. PubMed ID: 11602042
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.
    Pediatr Infect Dis J; 2005 Oct 20; 24(10):880-5. PubMed ID: 16220085
    [Abstract] [Full Text] [Related]

  • 11. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW, AIDS Clinical Trials Group 398 Study Team.
    JAMA; 2002 Jul 10; 288(2):169-80. PubMed ID: 12095381
    [Abstract] [Full Text] [Related]

  • 12. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.
    Antivir Ther; 2006 Jul 10; 11(4):421-9. PubMed ID: 16856615
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
    Breilh D, Pellegrin I, Rouzés A, Berthoin K, Xuereb F, Budzinski H, Munck M, Fleury HJ, Saux MC, Pellegrin JL.
    AIDS; 2004 Jun 18; 18(9):1305-10. PubMed ID: 15362663
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V, Lindkvist A, Bergroth T, Knut L, Sönnerborg A.
    J Med Virol; 2005 Aug 18; 76(4):447-51. PubMed ID: 15977242
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
    Raines CP, Flexner C, Sun E, Heath-Chiozzi M, Lewis RH, Fields C, Deetz C, Apuzzo L, Eshleman SH, Jackson JB, Gallant JE.
    J Acquir Immune Defic Syndr; 2000 Dec 01; 25(4):322-8. PubMed ID: 11114832
    [Abstract] [Full Text] [Related]

  • 20. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
    Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM, Narval Trial Group.
    Antivir Ther; 2003 Oct 01; 8(5):427-34. PubMed ID: 14640390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.